Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Marginal Zone B-cell Lymphoma

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Primary CNS Lymphoma: Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Primary CNS Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Primary CNS Lymphoma

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma...

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Nodal Marginal Zone B-Cell Lymphoma

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Secondary CNS Lymphoma: Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Secondary CNS Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Secondary CNS Lymphoma

Data Insights

Lisocabtagene maraleucel by Bristol-Myers Squibb for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia (CLL)